CD4 and COVID-19: In a study conducted by Riou et al. [55] they found that acute SARS-CoV-2 infection may not immediately result in progression of latent Mtb to subclinical or active TB disease but found a significant reduction of Mtb–specific CD4+ T cells in COVID-19 patients.